All Blogs
Feb 25, 2026
Electrophysiology Devices: The Future of Cardiac Arrhythmia Management
Cardiac electrophysiology is a specialized branch of cardiology that focuses on the heart's electrical system and the diagnosis and treatment of heart rhythm disorders, known as arrhythmias. The field has evolved from simple diagnostic recordings to a highly sophisticated discipline that utilizes robotics, advanced...
Read More...
Feb 24, 2026
Gilead Sciences to Acquire Arcellx in Strategic Move to Accelerate Anito-cel Development; Novo Nordisk Faces Setback as CagriSema Underwhelms Against Rival Therapy in Trial; Vanda Pharmaceuticals Secures FDA Approval for BYSANTI; All-oral Calquence + venetoclax Combo Clears in the US for First-line Treatment of CLL; Merck’s ENFLONSIA Demonstrates Strong Protection Against Severe RSV in Young Children Over Consecutive Seasons
Gilead Sciences Announces Acquisition of Arcellx to Advance Long-Term Growth of Anito-cel Gilead Sciences announced a definitive agreement to acquire Arcellx, a clinical-stage biotechnology company, in a strategic move to strengthen its leadership in cell therapy and oncology innovation. The acquisition builds o...
Read More...
Feb 23, 2026
Bone Marrow Failure: The Silent Global Crisis Driving a New Era of Therapeutic Innovation
Summary In 2024, the 7MM reported approximately 35,000 incident BMF cases, highlighting the persistent clinical burden and the ongoing need for earlier diagnosis and more effective treatment strategies. ROMIPLATE has made notable regulatory progress in Japan, its only approved market for aplastic anemia, ex...
Read More...
Feb 20, 2026
Tumor‑Infiltrating Lymphocyte (TIL) Therapies: Redefining Cell Therapy for Solid Tumors
Summary TIL therapy marks a major shift in solid-tumor immunotherapy, offering an effective approach where CAR-T strategies have struggled, broadening options beyond PD-1 and BRAF/MEK inhibitors for metastatic melanoma, and driving extensive clinical evaluation across NSCLC, HNSCC, CRC, pancreatic, prosta...
Read More...
Feb 19, 2026
Medtronic Wins FDA Green Light for Stealth AXiS; Retia Medical Secures FDA 510(k) Clearance for Argos Infinity; Danaher Announces Plan to Acquire Masimo Corporation; Dynarex Introduces New Advanced Negative Pressure Therapy Device; Valcare Medical Reports First U.S. Transseptal AMEND™ Implant in Early Feasibility Study; Envoy Medical Reports Enrollment Nearly Complete for Acclaim Cochlear Implant Pivotal Trial
Medtronic Received FDA Clearance for Stealth AXiS™ Surgical System, First Integrated Planning, Navigation and Robotics Platform for Spine Surgery On February 13, 2026, Medtronic, a global leader in healthcare technology, announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical sy...
Read More...
Feb 18, 2026
Diabetes Care Devices: Transforming Management Through Innovation and Precision
Diabetes care devices are becoming increasingly vital as the global burden of diabetes continues to rise. Today, more than 530 million adults worldwide live with diabetes, a number projected to increase in the future. The condition requires continuous monitoring and timely intervention to prevent serious complicati...
Read More...
Feb 17, 2026
Roche’s GAZYVA/GAZYVARO Achieves Key Phase III Success in Primary Membranous Nephropathy; Novartis’ VANRAFIA Slows Kidney Function Decline in Phase III IgA Nephropathy Trial; PTC Therapeutics Shares Latest Regulatory Developments for Translarna; BridgeBio’s Oral Infigratinib Achieves Key Body Proportionality Improvements in Phase 3 Achondroplasia Trial; Upstream Bio’s Verekitug Achieves Key Endpoints in Phase 2 Trial for Severe Asthma Treatment
Roche Reports Positive Phase III Data for GAZYVA/GAZYVARO in Primary Membranous Nephropathy Roche has reported highly encouraging results from the Phase III MAJESTY study, which evaluated the efficacy and safety of GAZYVA/GAZYVARO (obinutuzumab) in adults suffering from primary membranous nephropathy (PMN). PMN ...
Read More...
Feb 16, 2026
Alternative Therapeutic Strategies Beyond HSCT: Reimagining Curative Options in Hematologic Disease
Summary HSCT is a potentially curative treatment for hematologic malignancies (acute leukemias, lymphomas, multiple myeloma) and bone marrow failure syndromes. In 2025, approximately 26,000 HSCT cases were reported in the 7MM, with Multiple Myeloma/Plasma Cell Dyscrasias having the largest patient pool in th...
Read More...
Feb 13, 2026
The Next Frontier in Bardet–Biedl Syndrome Treatment: Gene Therapy and Beyond
Summary Bardet–Biedl syndrome (BBS) is a rare, genetically heterogeneous disorder that affects more than 5,000 individuals in the United States. A major therapeutic milestone was the approval of IMCIVREE (setmelanotide), the first targeted MC4R agonist therapy addressing BBS-related obesity. Gene th...
Read More...
Feb 12, 2026
Hologic Gains FDA Clearance for Aptima® HPV Assay as Primary Screening Tool; ZOLL Zenix Monitor/Defibrillator Achieves MDR Approval; Labcorp Unveils FDA-Cleared Blood Test for Alzheimer’s Screening; P&F SecureD EU MDR CE Mark Approval for the TricValve® System; Valcare Medical Performs First U.S. Transseptal AMEND™ Implant as Part of Early Feasibility Study; Hyperfine Unveils New Clinical Results Showing Improved Stroke Detection with the Swoop® System
Hologic Received FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio On February 04, 2026, Hologic, Inc. announced that its Aptima® HPV Assay had received FDA approval for clinician-collected HPV primary screening. The test, which was the only FDA-approved mRNA-...
Read More...